ID: ALA5208573

Max Phase: Preclinical

Molecular Formula: C44H56N6O5

Molecular Weight: 748.97

Representations

Canonical SMILES:  CC(C)(C)CNC(=O)C[C@H](NC(=O)N1CCC(C(=O)N2CCc3ccccc32)CC1)C(=O)N[C@@H](CCc1ccccc1)C(=O)N[C@@H]1CCCc2ccccc21

Standard InChI:  InChI=1S/C44H56N6O5/c1-44(2,3)29-45-39(51)28-37(48-43(55)49-25-22-33(23-26-49)42(54)50-27-24-32-15-8-10-19-38(32)50)41(53)47-36(21-20-30-12-5-4-6-13-30)40(52)46-35-18-11-16-31-14-7-9-17-34(31)35/h4-10,12-15,17,19,33,35-37H,11,16,18,20-29H2,1-3H3,(H,45,51)(H,46,52)(H,47,53)(H,48,55)/t35-,36+,37+/m1/s1

Standard InChI Key:  VDDAECJAVAAAEC-BOALQFNTSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 748.97

Molecular Weight (Monoisotopic): 748.4312

AlogP: 5.23

#Rotatable Bonds: 12

Polar Surface Area: 139.95

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: 2

HBA (Lipinski): 11

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 12.56

CX Basic pKa:

CX LogP: 4.86

CX LogD: 4.86

Aromatic Rings: 3

Heavy Atoms: 55

QED Weighted: 0.20

Np Likeness Score: -0.87

References

1. Cao Y, Tu Y, Fu L, Yu Q, Gao L, Zhang M, Zeng L, Zhang C, Shao J, Zhu H, Zhou Y, Li J, Zhang J..  (2022)  Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.,  233  [PMID:35218994] [10.1016/j.ejmech.2022.114211]

Source

Source(1):

• Scientific Literature